Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

March 31, 2016

Study Completion Date

June 24, 2016

Conditions
AngiosarcomasSoft Tissue Sarcoma
Interventions
DRUG

Bevacizumab

15 mg/kg, IV every 21 days x 6 cycles.

DRUG

Paclitaxel

"Regimen A / Treatment 1: 200 mg/m² IV over 3 hours every 21 days.~Regimen B / Treatment 2: 90 mg/m² weekly x 3 of a 28-day cycle"

Trial Locations (3)

77030

MD Anderson Sarcoma Center, Houston

90403

Santa Monica Sarcoma Center, Santa Monica

94305

Stanford University Medical Center, Stanford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Stanford University

OTHER